Which is better, liraglutide or setmelanotide?
The choice follows the diagnosis. For common obesity, liraglutide is approved and setmelanotide is not indicated. For obesity caused by a confirmed defect in the leptin to melanocortin pathway, or by hypothalamic injury, setmelanotide is the drug approved for that cause and restores the missing satiety signal directly. They have never been compared. [1] [2] [3] [4]
How do liraglutide and setmelanotide compare?
| Dimension | Liraglutide | Setmelanotide |
|---|---|---|
| Who it is for [1] [2] [4] [5] | Adults and adolescents 12 and older with obesity or overweight with a weight related condition (Saxenda); adults and children 10 and older with type 2 diabetes (Victoza). | Imcivree: chronic weight management in obesity due to POMC, PCSK1, or LEPR deficiency (2020) or Bardet-Biedl syndrome (2022), extended to age 2 and older in December 2024, and acquired hypothalamic obesity in patients 4 and older (March 2026). Not indicated for common obesity. |
| Mechanism [1] [2] | GLP-1 receptor agonist: slows gastric emptying and reduces appetite through gut hormone signaling. | Melanocortin-4 receptor agonist: restores the hypothalamic satiety signal lost when the leptin to POMC to MC4R pathway is broken. |
| Weight loss evidence [3] [4] [6] | SCALE (3,731 adults, 56 weeks): 8.4 kg versus 2.8 kg on placebo; 63.2% lost at least 5%. | 80% of POMC or PCSK1 deficient and 45% of LEPR deficient patients lost at least 10% at one year (single arm phase 3); acquired hypothalamic obesity: BMI 15.8% lower versus 2.6% higher on placebo at 52 weeks. |
| Side effects [1] [2] | Nausea, diarrhea, constipation, vomiting; gallbladder disease; heart rate up 2 to 3 beats per minute; thyroid C-cell boxed warning. | Injection site reactions, skin darkening and hyperpigmentation, nausea, spontaneous erections, and a label warning about depression and suicidal ideation. |
| Dosing [1] [2] | Once daily injection, 0.6 mg escalated weekly to 3.0 mg. | Once daily injection; adults start at 2 mg and increase to 3 mg; weight based dosing in young children. |
| Regulatory status [1] [2] [4] [7] | FDA approved (Victoza 2010, Saxenda 2014); generics approved from December 2024. | FDA approved (Imcivree 2020, with expansions in 2022, 2024, and March 2026). Prescription only for the labeled conditions. |
| WADA status [8] | Not on the WADA Prohibited List. | Not on the WADA Prohibited List. |
Evidence grade and regulatory status
Pulled from each peptide’s own record, so it stays in step with the peptide pages.
| Attribute | Liraglutide | Setmelanotide |
|---|---|---|
| Class | GLP-1 receptor agonist (acylated analog of human GLP-1, 97% sequence homology, once daily dosing) | Cyclic 8 amino acid melanocortin-4 receptor (MC4R) agonist |
| What it is | First daily GLP-1 drug: FDA approved since 2010, about 8% weight loss at 3 mg over 56 weeks, proven heart benefit, now available as a generic. | FDA approved hunger-pathway (MC4R) drug for rare genetic obesity (POMC, PCSK1, LEPR, Bardet-Biedl) and acquired hypothalamic obesity; not for common obesity. |
| Evidence | Evidence: Human RCT evidence | Evidence: Human RCT evidence |
| FDA status | Regulatory: FDA approved | Regulatory: FDA approved |
| Compounding | FDA approved products (Victoza January 2010, Saxenda December 2014). FDA approved the first generic liraglutide referencing Victoza in December 2024, and generic products referencing Saxenda followed in 2025, so branded, generic, and authorized generic pens are all on the market. FDA listed liraglutide injection as in shortage in its October 2024 and February 2025 GLP-1 updates, and FDA's Drug Shortages database still lists it as of September 27, 2026 (first posted July 18, 2023; updated September 22, 2026), with Victoza and Saxenda presentations at limited availability and unbranded presentations available. FDA states that a compounded drug may not be identical or nearly identical to an FDA-approved drug unless the approved drug is on FDA's drug shortage list. On April 30, 2026 FDA proposed not to include liraglutide on the 503B bulks list; that proposal was not final as of September 2026. Ask any pharmacy offering compounded liraglutide which FDA rule it relies on. | FDA approved product (Imcivree, November 2020 for POMC, PCSK1, and LEPR deficiency obesity; June 2022 for Bardet-Biedl syndrome; December 2024 expansion to ages 2 and older). It is available only by prescription and requires a confirmed genetic diagnosis for coverage. Because an approved product exists and is not in shortage, compounding is not permitted except for a documented patient specific clinical need. Setmelanotide is not on any FDA compounding bulks list. The current label also covers acquired hypothalamic obesity in patients 4 years and older. |
| WADA | WADA: Not WADA prohibited | WADA: Not WADA prohibited |
| Routes | Subcutaneous injection once daily (prefilled pen) | Subcutaneous injection once daily |
| Typical cost | Manufacturer list price is 1,349.02 USD per month for Saxenda and 543.51 to 815.27 USD per month for Victoza depending on the daily dose (checked 2026-09-22). Generic liraglutide pens cost from about 112 USD per month for the diabetes strength and about 372 USD for the 3 mg weight management generic with a discount card, against average retail prices of about 616 to 924 USD. With commercial insurance the Saxenda savings card can bring a covered prescription to 25 USD. Medicare Part D covers liraglutide for type 2 diabetes but generally not for weight loss alone, and the Medicare GLP-1 Bridge does not include it. | List price is in the hundreds of thousands of USD per year. Patients with a confirmed qualifying genetic diagnosis are usually covered by insurance with manufacturer support programs; out of pocket cost without coverage is prohibitive. |
| Last verified |
Has liraglutide been tested directly against setmelanotide?
No published trial has compared liraglutide and setmelanotide directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.
What do liraglutide and setmelanotide cost?
| Dimension | Liraglutide | Setmelanotide |
|---|---|---|
| Typical cost | $112 to $1,349 per month | List price is in the hundreds of thousands of USD per year. Patients with a confirmed qualifying genetic diagnosis are usually covered by insurance with manufacturer support programs; out of pocket cost without coverage is prohibitive. |
| Price detail | Liraglutide price by channel | Price index in progress |
Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.
Frequently asked questions
Can setmelanotide be used for ordinary weight loss?
No. It is approved only for obesity due to POMC, PCSK1, or LEPR deficiency, Bardet-Biedl syndrome, or acquired hypothalamic obesity, and the label excludes common obesity. [2] [4]
Which is better for hypothalamic obesity?
Setmelanotide is the approved option: in March 2026 FDA approved it for acquired hypothalamic obesity in patients 4 and older after a phase 3 trial showed an 18.4% greater BMI reduction than placebo at 52 weeks. Liraglutide is not labeled for this condition. [1] [4]
Are both daily injections?
Yes. Both liraglutide and setmelanotide are injected under the skin once a day. [1] [2]
What side effects are unique to setmelanotide?
Skin and mole darkening, spontaneous erections, and a warning to monitor for depression and suicidal thoughts, none of which are typical of liraglutide. [1] [2]
Conditions studied
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]FDA prescribing information for Saxenda (liraglutide) injection, via DailyMedFDA
- [2]FDA prescribing information for Imcivree (setmelanotide) injection, via DailyMedFDA
- [3]Clement K et al. Efficacy and safety of setmelanotide in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol 2020PubMed 33137293, 2020
- [4]Trade press report: FDA approves setmelanotide for acquired hypothalamic obesity in patients 4 and older (March 19, 2026), accessed 2026-09-222026
- [5]FDA prescribing information for Victoza (liraglutide) injection, via DailyMedFDA
- [6]Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015 (SCALE Obesity and Prediabetes)PubMed 26132939, 2015
- [7]FDA: First generic drug approvals (includes liraglutide injection, December 2024)FDA
- [8]WADA Prohibited List (section S0 covers substances not approved by any government health authority)WADA
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 22). Liraglutide vs setmelanotide: evidence, cost, and legality. https://peptideagent.ai/compare/liraglutide-vs-setmelanotide- HTML link
<a href="https://peptideagent.ai/compare/liraglutide-vs-setmelanotide">Liraglutide vs setmelanotide: evidence, cost, and legality</a>, PeptideAgent, updated September 22, 2026.